Objective: Lactase persistence (LP), the ability to maintain a high lactase activity throughout life, has been suggested to be a possible risk factor for diabetes. Recently, a single nucleotide polymorphism C (À13910) T, residing 14 kb from the 5 0 end of the lactase (LCT) gene was shown to be associated with LP. Here we have studied the relationship between C (13910) T polymorphism and diabetes in the Finnish population. Patients and design: In all, 1455 patients with type I and 615 with type II diabetes and 446 nondiabetic controls in the Finnish population were genotyped for the C (-13910) T polymorphism by PCR minisequencing. Results: No differences were detected in the LP genotype frequencies (CT&TT) between diabetic and nondiabetic subjects. Conclusions: We conclude that the C (À13910) T polymorphism associated with lifelong LP is not a risk factor for type I or type II diabetes in the Finnish population.
The incidence of diabetes is increasing worldwide, and is strongly associated with obesity and a westernised lifestyle (Zimmet et al, 2001) . Milk and milk products form an essential part of the Western diet. In a recent report, a high frequency of lactose absorbers was observed among diabetic patients in Sardinia (Meloni et al, 2001) . In this respect, it is noteworthy that Sardinia and Finland represent populations with the highest incidence of type I diabetes in the world (Tuomilehto et al, 1999) . Interestingly, Finland has the highest annual consumption of milk products with an average of 220 kg milk products per capita, and thus a high frequency of lactose absorption among diabetic patients is intriguing.
Lactose, the main sugar of milk, is digested to glucose and galactose by lactase in the gut, and the activity of this enzyme normally declines after weaning to 5-10% of that in infancy. Primary lactose malabsorption (LM) is an autosomal recessive condition, while lactase persistence (LP) is inherited as a dominant single gene trait (Sahi et al, 1973; Sahi, 1994) . LM can be manifested clinically as lactose intolerance (LI) by flatulence, bloating, distension, diarrhoea and abdominal pain, causing many people to avoid drinking milk (Birge et al, 1967) . In humans, intestinal lactase activity is increased in diabetes and has been shown to normalise on insulin treatment (Tandon et al, 1975) . Furthermore, milk lipids containing high amounts of energy might contribute to obesity and an increased risk for diabetes.
We have recently identified a single nucleotide polymorphism (SNP), a C to T change residing 13910 base pairs upstream of the lactase (LCT) gene on chromosome 2q21-22 that exhibits a complete association with LM. The genotype CC is associated with LM and genotypes CT and TT with LP (Enattah et al, 2002) . Importantly, the three genotypes correlate with the level of the disaccharidase activities in intestinal biopsy samples and their L/S ratio (Enattah et al, 2002; Kuokkanen et al, 2003) . Functional evidence for the nonpersistent C À13910 allele and persistent T À13910 allele has recently been obtained by relative quantitation of the expressed LPH alleles that show several times higher expression of LPH mRNA in the intestinal mucosa in individuals with the T À13910 allele compared to that found in individuals with the C À13910 allele, suggesting regulation of the LPH gene at the transcriptional level (Kuokkanen et al, 2003) . This is in agreement with recent functional studies reporting greater increase in lactase promoter activity by the T À13910 variant using Luciferase reporter constructs (Olds & Sibley, 2003; Troelsen et al, 2003) .
To assess a potential role of LP in the pathogenesis of diabetes, we genotyped 2542 Finnish subjects for the C (-13910) T polymorphism including 1455 type I diabetes (Pettersson-Fernholm et al, 2003) , 615 type II diabetes patients and 446 control subjects (Groop et al, 1996) (Table 1) .
Type I diabetes patients recruited from the populationbased FinnDiane Study had an onset of diabetes below 35 y and permanent insulin treatment initiated within 1 y of diagnosis. We randomly selected 495 type II diabetes patients from Western Finland and 120 from Eastern Finland participating in the Botnia study and 446 control subjects from Western Finland (Groop et al, 1996) classified according to the revised WHO criteria (Alberti & Zimmet, 1998) . Families with maturity-onset diabetes of the young or mitochondrial diabetes were excluded after DNA analysis (Lehto et al, 1997) . Spouses without first-or second-degree family history of diabetes were chosen as control subjects. All subjects were negative for glutamic acid decarboxylase antibodies (GADab).
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Waist circumference was measured with a soft tape on standing patients midway between the lowest rib and the iliac crest. Hip circumference was measured over the widest part of the gluteal region, and waist-to-hip ratio (WHR) was calculated. Fasting blood glucose was measured by the hexokinase method (Boehringer Mannheim, Mannheim, Germany) and HbA 1c concentration by HPLC. The study protocols were approved by the local ethics committees and followed the principles laid down in the Declaration of Helsinki.
Genomic DNA was extracted from samples of peripheral venous blood according to standard procedures, and the DNA fragment spanning the C/T À13910 variant was amplified using a biotinylated and an unbiotinylated primer and minisequenced as described (Syvanen et al, 1993) . Two parallel minisequencing reactions were carried out for each PCR product. All data are expressed as mean 7s.e.m.
Differences between group means were tested with analysis of variance or the Mann-Whitney U-test when appropriate. Frequency differences were analysed with Pearson's w 2 test.
All statistical analysis was performed using the BMDP statistical package (BMDP Statistical Software, Los Angeles, CA, USA). A P-value less than 0.05 was considered to be statistically significant. The frequency of LP genotypes (CT and TT) was 84.7% in type I diabetic patients and did not differ from the frequency of 81.9% in the general population (Enattah et al, 2002) . Patients with the CC genotype were slightly younger and had a shorter duration of diabetes (P ¼ 0.02) ( Table 2 ). The frequency of CT and TT genotypes among 465 type II diabetic patients from Western Finland was 91.7 vs 91.3% in 446 control subjects from the same region (P ¼ NS). Among 120 patients with type II diabetes patients from Eastern Finland, the prevalence of the persistence CT and TT genotypes was 82.5 vs 81.1% in the general population of Eastern Finland (Enattah et al, 2002) (Table 2 ). The LP genotypes were associated with WHR in type 2 diabetic females from Western Finland (P ¼ 0.03) and in type II diabetic males from Eastern Finland (P ¼ 0.03) ( Table 2) .
The present study, including 2516 subjects, could not demonstrate any association between LP genotypes and type I or type II diabetes. This suggests that lactase persistence is not a risk factor for diabetes in Finland, and contradicts the Lactase persistence and diabetes NS Enattah et al finding obtained in the Sardinians (Meloni et al, 2001) . It also highlights the methodology and importance of subject selection in a case-control study of lactase persistence to avoid false positive associations when the prevalence of the condition varies considerably among and between populations (Sahi, 1994) . Given the association between WHR and the LP genotypes, an effect of the consumption of milk products on obesity and especially on abdominal obesity cannot be ruled out. Further studies are warranted concerning this association.
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